{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-089147","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2026-08-13T20:30:17+00:00","discovered_at":"2026-08-13T20:32:00.399925+00:00","generated_at":"2026-08-13T20:32:31.161875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal Q2 net loss narrows to $3.3M; Phase 2 CAD-1005 cuts thrombotic events >25%","bullets":["Q2 2026 net loss of $3.3M vs $3.7M in Q2 2025; R&D expenses $0.7M vs $1.1M; G&A $2.6M vs $2.7M.","Cash ~$4.2M as of early August 2026, expected to fund operations through Q1 2027; not sufficient for clinical trials.","Phase 2 CAD-1005 data at ISTH 2026 Congress in Paris showed >25% absolute reduction in thrombotic events.","Launched structured partnering process for CAD-1005, frunexian, and tecarfarin; pursuing out-licensing model.","Private placement raised ~$3.0M gross proceeds, up to ~$5.8M more if warrants fully exercised."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-089147","json":"https://secwatch.observer/filing/0001213900-26-089147.json","markdown":"https://secwatch.observer/filing/0001213900-26-089147.md","text":"https://secwatch.observer/filing/0001213900-26-089147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/0001213900-26-089147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/ea0302042-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:32:31.161875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}